DLBS 3233

Drug Profile

DLBS 3233

Alternative Names: DLBS-3233; Inlacin

Latest Information Update: 11 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dexa Medica
  • Class Antihyperglycaemics; Thiazolidinediones
  • Mechanism of Action Adiponectin stimulants; GLUT4 stimulants; Lipoprotein modulators; Peroxisome proliferator-activated receptor gamma modulators; Phosphatidylinositol 3 kinase alpha modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Polycystic ovary syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Jun 2015 No recent reports of development identified - Phase-III for Type-2 diabetes mellitus (Prevention) in Indonesia (PO)
  • 01 Oct 2014 Dexa Medica initiates enrolment in the phase III PROSTIF trial for Polycystic ovary syndrome in Indonesia (NCT01999686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top